{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T04:06:56Z","timestamp":1728533216163},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"DOI":"10.7759\/cureus.71106","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T03:33:36Z","timestamp":1728444816000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of the \u03b23-Adrenoceptor Agonist Vibegron for Urgency and Mixed Urinary Incontinence: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study"],"prefix":"10.7759","author":[{"given":"Masaki","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Nawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kubono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.11.078","article-title":"Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence","volume":"76","author":"Buckley BS","year":"2010","unstructured":"Buckley BS, Lapitan MC. Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence. Urology. 2010, 76:265-70. 10.1016\/j.urology.2009.11.078","journal-title":"Urology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12164","article-title":"Comorbidities and personal burden of urgency urinary incontinence: a systematic review","volume":"67","author":"Coyne KS","year":"2013","unstructured":"Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013, 67:1015-33. 10.1111\/ijcp.12164","journal-title":"Int J Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15454","article-title":"Prevalence and impact on daily life of lower urinary tract symptoms in Japan: results of the 2023 Japan Community Health Survey (JaCS 2023)","volume":"31","author":"Mitsui T","year":"2024","unstructured":"Mitsui T, Sekido N, Masumori N, et al.. Prevalence and impact on daily life of lower urinary tract symptoms in Japan: results of the 2023 Japan Community Health Survey (JaCS 2023). Int J Urol. 2024, 31:747-54. 10.1111\/iju.15454","journal-title":"Int J Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams P","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, et al.. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003, 61:37-49. 10.1016\/s0090-4295(02)02243-4","journal-title":"Urology"},{"key":"ref5","article-title":"Diagnosis of urinary incontinence","volume":"87","author":"Khandelwal C","year":"2013","unstructured":"Khandelwal C, Kistler C. Diagnosis of urinary incontinence. Am Fam Physician. 2013, 87:543-50.","journal-title":"Am Fam Physician"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence","volume":"82","author":"Nambiar AK","year":"2022","unstructured":"Nambiar AK, Arlandis S, B\u00f8 K, et al.. European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022, 82:49-59. 10.1016\/j.eururo.2022.01.045","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida M","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018, 73:783-90. 10.1016\/j.eururo.2017.12.022","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2022.100674","article-title":"Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors","volume":"96","author":"Brucker BM","year":"2022","unstructured":"Brucker BM, King J, Mudd PN Jr, McHale K. Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors. Curr Ther Res Clin Exp. 2022, 96:100674. 10.1016\/j.curtheres.2022.100674","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290685","article-title":"Vibegron shows high selectivity and potent agonist activity for \u03b23-adrenoceptors, irrespective of receptor density","volume":"18","author":"Yamamoto S","year":"2023","unstructured":"Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. Vibegron shows high selectivity and potent agonist activity for \u03b23-adrenoceptors, irrespective of receptor density. PLoS One. 2023, 18:e0290685. 10.1371\/journal.pone.0290685","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15020","article-title":"Efficacy of vibegron, a novel \u03b23-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study","volume":"125","author":"Yoshida M","year":"2020","unstructured":"Yoshida M, Takeda M, Gotoh M, et al.. Efficacy of vibegron, a novel \u03b23-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020, 125:709-17. 10.1111\/bju.15020","journal-title":"BJU Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","article-title":"A new questionnaire to assess the quality of life of urinary incontinent women","volume":"104","author":"Kelleher CJ","year":"1997","unstructured":"Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997, 104:1374-9. 10.1111\/j.1471-0528.1997.tb11006.x","journal-title":"Br J Obstet Gynaecol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.379","article-title":"Validation of two global impression questionnaires for incontinence","volume":"189","author":"Yalcin I","year":"2003","unstructured":"Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003, 189:98-101. 10.1067\/mob.2003.379","journal-title":"Am J Obstet Gynecol"},{"key":"ref13","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang KY","year":"2000","unstructured":"Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ser B. 2000, 62:134-48.","journal-title":"Sankhya Ser B"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-011-1503-3","article-title":"Urinary incontinence self-report questions: reproducibility and agreement with bladder diary","volume":"22","author":"Bradley CS","year":"2011","unstructured":"Bradley CS, Brown JS, Van Den Eeden SK, Schembri M, Ragins A, Thom DH. Urinary incontinence self-report questions: reproducibility and agreement with bladder diary. Int Urogynecol J. 2011, 22:1565-71. 10.1007\/s00192-011-1503-3","journal-title":"Int Urogynecol J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14700","article-title":"Efficacy of mirabegron, a \u03b2(3)-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies","volume":"29","author":"Takahashi S","year":"2022","unstructured":"Takahashi S, Mishima Y, Kuroishi K, Ukai M. Efficacy of mirabegron, a \u03b2(3)-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol. 2022, 29:7-15. 10.1111\/iju.14700","journal-title":"Int J Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2022.07.012","article-title":"Urodynamic evaluation of the efficacy of vibegron, a new \u03b23-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder","volume":"18","author":"Kitta T","year":"2022","unstructured":"Kitta T, Chiba H, Kon M, et al.. Urodynamic evaluation of the efficacy of vibegron, a new \u03b23-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. J Pediatr Urol. 2022, 18:563-9. 10.1016\/j.jpurol.2022.07.012","journal-title":"J Pediatr Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14720","article-title":"Video-urodynamic effects of vibegron, a new selective \u03b23-adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida","volume":"29","author":"Aoki K","year":"2022","unstructured":"Aoki K, Momose H, Gotoh D, et al.. Video-urodynamic effects of vibegron, a new selective \u03b23-adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida. Int J Urol. 2022, 29:76-81. 10.1111\/iju.14720","journal-title":"Int J Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14658","article-title":"\u03b2(3)-adrenoceptors in the normal and diseased urinary bladder-what are the open questions?","volume":"176","author":"Igawa Y","year":"2019","unstructured":"Igawa Y, Aizawa N, Michel MC. \u03b2(3)-adrenoceptors in the normal and diseased urinary bladder-what are the open questions?. Br J Pharmacol. 2019, 176:2525-38. 10.1111\/bph.14658","journal-title":"Br J Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(00)00232-8","article-title":"A community-based epidemiological survey of female urinary incontinence: the Norwegian Epincont study. Epidemiology of incontinence in the county of Nord-Tr\u00f8ndelag","volume":"53","author":"Hannestad YS","year":"2000","unstructured":"Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: the Norwegian Epincont study. Epidemiology of incontinence in the county of Nord-Tr\u00f8ndelag. J Clin Epidemiol. 2000, 53:1150-7. 10.1016\/s0895-4356(00)00232-8","journal-title":"J Clin Epidemiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/287330-comparative-efficacy-and-safety-of-the-3-adrenoceptor-agonist-vibegron-for-urgency-and-mixed-urinary-incontinence-a-post-hoc-analysis-of-a-randomized-double-blind-placebo-controlled-phase-3-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T03:33:40Z","timestamp":1728444820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/287330-comparative-efficacy-and-safety-of-the-3-adrenoceptor-agonist-vibegron-for-urgency-and-mixed-urinary-incontinence-a-post-hoc-analysis-of-a-randomized-double-blind-placebo-controlled-phase-3-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.71106","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}